Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TATEMENT	OF CH	ANGES IN	I BENEFICIAL	. OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bracken Sharon J</u>					2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]											k all applic Directo	icable) or		erson(s) to Issuer 10% Owner Other (conside		
(Last) 100 ABI	(F BOTT PAR	•	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/22/2019											X	below)	er (give title Other (spec w) below) Senior Vice President			респу
(Street)	T PARK II	L	60064		4.1	If Ame	endment, I	Date o	of Oriç	ginal Fi	led	(Month/Da	ay/Yea	ar)		6. Indi Line) X	Form fi	led by One	e Repo	(Check Apporting Person One Repor	n
(City)	(5	State)	(Zip)														Persor				
		Tak	ole I - No	n-Deriv	vativ	e Se	curities	s Ac	quir	red, D	isp	osed o	f, or	Ben	efici	ially	Owned				
Di			2. Trans Date (Month	saction /Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Securit Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	r Indirect (r Indirect (str. 4)	7. Nature of Indirect Beneficial Ownership		
									С	ode	,	Amount		(A) or (D)	Pric	ce	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common shares without par value			02/2	2/201	/2019			Α		17,292(1)		A	\$	00	56,321			D			
Common shares without par value															760(2)			I :	Profit Sharing Trust		
			Table II -									sed of, onvertil					wned			•	•
1. Title of Derivative Security (Instr. 3) 2. Conversi or Exerci Price of Derivativ Security		cise (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Transaction					6. Date Exercisa Expiration Date (Month/Day/Year				7. Title and Ame of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Securi	[Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Silly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title		Amou or Numb of Share	ber					
Option (right to	\$75.9	02/22/2019			A		90,642		02/2	22/2020	03	2/21/2029		nmon ares	90,6	42	\$0	90,642	2	D	

Explanation of Responses:

- 1. These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
- 2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 22, 2019.
- 3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,214 on February 22, 2020, 30,214 on February 22, 2021, and 30,214 on February 22, 2022.

Jessica H. Paik, by power of attorney for Sharon J. Bracken

02/26/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, including a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: December 18, 2018

/s/ Sharon J. Bracken Signature of Reporting Person

Sharon J. Bracken

Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064